Tesofensine for Weight Loss & Appetite Suppression — Weight & Metabolism
Triple monoamine reuptake inhibitor targeting serotonin, dopamine, and norepinephrine for significant appetite suppression and weight reduction.
Overview
Tesofensine is a novel triple monoamine reuptake inhibitor (TRI) that blocks reuptake of serotonin, dopamine, and norepinephrine, originally developed for Alzheimer's and Parkinson's disease by NeuroSearch A/S. During Phase 2 neurological trials, significant weight loss was observed as a side effect, leading to repositioning as an anti-obesity agent. The Phase 2 TIPO-1 trial (Astrup et al., Lancet 2008, PMID: 18832164, n=203, 24 weeks) demonstrated dose-dependent weight loss: 4.5% at 0.25mg, 9.2% at 0.5mg, and 10.6% at 1.0mg vs 2.0% placebo. The 0.5mg dose showed the best risk-benefit profile with 12.8% total weight loss including dietary intervention. Tesofensine produces approximately 2x the weight loss of sibutramine. Phase 3 trials are being conducted by Saniona (Denmark). The compound reduces appetite primarily through dopaminergic and serotonergic satiety pathways and increases resting energy expenditure via noradrenergic thermogenesis. NOT FDA-approved. Not yet commercially available.
Indications
- Obesity (BMI >=30) or overweight with comorbidities (Phase 3 investigational)
- Appetite suppression and caloric intake reduction
- Metabolic rate enhancement via noradrenergic thermogenesis
Mechanism of Action
Insufficient monoamine signaling in hypothalamic satiety centers leads to excessive caloric intake and reduced thermogenesis
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Tesofensine | 0.25 mg | Once daily (morning) | Initial dose for 2-4 weeks to assess tolerance; 4.5% weight loss in Phase 2 |
| Tesofensine | 0.5 mg | Once daily (morning) | Optimal dose from Phase 2 (12.8% weight loss at 24 weeks); best risk-benefit ratio |
Evidence Grade
GRADE B
Safety & Contraindications
- NOT FDA-approved; Phase 3 trials ongoing (Saniona/Medix)
- Increases heart rate (5-8 bpm average) and may increase blood pressure at higher doses
- Contraindicated with MAOIs, SSRIs, SNRIs due to serotonin/norepinephrine interactions
- Insomnia, dry mouth, constipation, and diarrhea reported in Phase 2 trials
- 1.0mg dose associated with higher cardiovascular and psychiatric adverse events; 0.5mg preferred
- Not recommended in uncontrolled hypertension, history of cardiovascular disease, or psychiatric disorders